Cystic Fibrosis
📧 Sign up to get email alerts when something new happens for Cystic Fibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-03-20Clinical Trial Update: A Study of RPL554 in Patients With Cystic Fibrosis [Phase 2]
Phase 2 study of RPL554 in cystic fibrosis completed; results have been posted.
-
CLINICAL_TRIALS trial_result · 2019-03-14Clinical Trial Update: Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia [NA]
A completed clinical trial comparing CO2 monitoring methods in cystic fibrosis patients undergoing general anesthesia, with results posted i…
-
CLINICAL_TRIALS research · 2019-03-05Clinical Trial Update: Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis [NA]
Clinical trial update on airway clearance therapies in cystic fibrosis, with completed status and results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-02-26Clinical Trial Update: Effects of Sildenafil on CFTR-dependent Ion Transport Activity [Phase 2]
Phase 2 trial assessing sildenafil effects on CFTR-dependent ion transport in cystic fibrosis patients has completed with posted results.
-
CLINICAL_TRIALS research · 2019-02-22Clinical Trial Update: Chest Wall Motion Analysis in Disease
This completed clinical trial examines chest wall motion analysis across several diseases, including mesothelioma, lung cancer, COPD, cystic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-02-11FDA Approved: CAYSTON — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for Cayston (aztreonam) submitted by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2019-02-06Clinical Trial Update: Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients [Phase 1, Phase 2]
A dose-escalation Phase 1/2 trial of QR-010 in adults with homozygous ΔF508 cystic fibrosis has completed. Results were posted in February 2…
-
CLINICAL_TRIALS other · 2019-02-01Clinical Trial Update: The EPIC Observational Study
The EPIC Observational Study sponsored by the CF Therapeutics Development Network Coordinating Center has completed (status: COMPLETED). The…
-
CLINICAL_TRIALS trial_result · 2019-01-31Clinical Trial Update: Kinetics of YKL-40 Protein in Serum of Cystic Fibrosis Patients
This completed clinical trial evaluated the kinetics of the YKL-40 protein in the serum of cystic fibrosis patients.
-
CLINICAL_TRIALS trial_result · 2019-01-30Clinical Trial Update: Impact of Art Therapy on Anxiety Identified During Hospitalizations Among Children With Cystic Fibrosis Aged 8 to 13
A completed clinical trial assessed whether art therapy reduces anxiety during hospitalizations among children aged 8 to 13 with cystic fibr…
-
CLINICAL_TRIALS trial_result · 2019-01-30Clinical Trial Update: Perceived Impact of Art Therapy in Patients With Cystic Fibrosis and in Professional Interdisciplinary Teams Taking Care of Them.
This clinical trial update assesses the perceived impact of art therapy on patients with cystic fibrosis and on the professional interdiscip…
-
CLINICAL_TRIALS research · 2019-01-25Clinical Trial Update: WGS of Korean Idiopathic Bronchiectasis
This update reports ongoing whole-genome sequencing research on idiopathic bronchiectasis in Korean patients, with related conditions includ…
-
CLINICAL_TRIALS withdrawal · 2019-01-10Clinical Trial Update: Growth Hormone Treatment Study in Children With Cystic Fibrosis [Phase 2, Phase 3]
A growth hormone treatment trial in children with cystic fibrosis was withdrawn after Phase 2/3 enrollment.
-
CLINICAL_TRIALS trial_result · 2019-01-08Clinical Trial Update: A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor [Phase 3]
Phase 3 study evaluating tezacaftor in combination with ivacaftor in CF patients aged 12+ with one F508del-CFTR mutation and a responsive se…
-
FDA approval · 2018-12-20FDA Approved: TOBI — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for TOBI (tobramycin) from Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2018-11-27Clinical Trial Update: Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis [Phase 4]
Phase 4 study reporting steady-state pharmacokinetics of ceftazidime/avibactam in patients with cystic fibrosis; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) [Phase 2]
A Phase 2 clinical trial update on the Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) for cystic fibrosi…
-
CLINICAL_TRIALS trial_result · 2018-11-19Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation [Phase 3]
A Phase 3 trial evaluating ivacaftor in children aged 3-5 with a CFTR gating mutation in cystic fibrosis has been terminated with results po…
-
CLINICAL_TRIALS trial_result · 2018-11-16Clinical Trial Update: A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis [Phase 2]
Phase 2 trial update for GLPG2222 in adults with cystic fibrosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-11-05Clinical Trial Update: To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration [Phase 1]
Phase 1 clinical trial assessing safety, tolerability, and pharmacokinetics of AZD5634 via inhaled and IV administration in cystic fibrosis …
-
CLINICAL_TRIALS trial_result · 2018-10-30Clinical Trial Update: Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del [Phase 3]
Clinical trial update reporting safety and pharmacokinetics of Lumacaftor/Ivacaftor in young children (2-5 years) with cystic fibrosis homoz…
-
CLINICAL_TRIALS trial_result · 2018-10-26Clinical Trial Update: Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic Fibrosis [NA]
A completed clinical trial evaluating the effects of adding an exercise program to pulmonary rehabilitation in patients with cystic fibrosis…
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa [Phase 4]
Phase 4 clinical trial evaluating lung clearance index in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; the study …
-
FDA approval · 2018-10-05FDA Approved: TOBI — Supplemental Application (Viatris Specialty LLC)
FDA approves a supplemental application for TOBI (tobramycin) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2018-10-05Clinical Trial Update: 18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients [Phase 3]
Phase 3 trial evaluating 18FDG-PET imaging to detect changes in airway inflammation in cystic fibrosis patients.